1-8 of 8
Robert C. Newton
Close
Sort by
Journal Articles

Plasma Biomarker Association with Response in Acute GVHD Subjects Treated with the Combination of Itacitinib and Corticosteroids in a Phase 1 Clinical Trial

Michael A. Pratta, MSc, Hao Liu, PhD, Michael C. Arbushites, Robert C Newton, PhD, Michael D. Howell, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4559.
https://doi.org/10.1182/blood-2018-99-116330
Published: 2018
Journal Articles

Cell-of-Origin Subtype Prediction of Diffuse Large B-Cell Lymphoma Using Gene Expression and Proteomic Data

Huiqing Liu, PhD, Jin Lu, PhD, Zhiwan Dong, PhD, Hao Liu, PhD, Edward Salinas, MSc, Sherry Owens, PhD, Michael A. Pratta, MSc, Michael F. Smith, PhD, Hiroomi Tada, MD PhD, Robert C Newton, PhD, Timothy Burn, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1712.
https://doi.org/10.1182/blood-2018-99-116949
Published: 2018
Journal Articles

Janus Kinase (Jak) 1 Inhibition Affects Both Megakaryopoiesis and Thrombopoiesis

Danuta Jadwiga Jarocha, PhD, Paul Gadue, PhD, Wei Tong, PhD, Robert C Newton, PhD, Mortimer Poncz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2559.
https://doi.org/10.1182/blood-2018-99-115407
Published: 2018
Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD
Journal: Blood
Blood (2016) 128 (22): 4195.
https://doi.org/10.1182/blood.V128.22.4195.4195
Published: 2016
Journal Articles

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Clinical Trials & Observations
Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, Jan Burger, Jorge Cortes, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Peggy A. Scherle, Robert C. Newton, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2012) 119 (20): 4614–4618.
https://doi.org/10.1182/blood-2011-12-400051
Published: 2012
Journal Articles

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish, Gengjie Yang, Qian Wang, Kathy Wang, Lynn Leffet, Michael J. Hansbury, Beth Thomas, Mark Rupar, Paul Waeltz, Kevin J. Bowman, Padmaja Polam, Richard B. Sparks, Eddy W. Yue, Yanlong Li, Richard Wynn, Jordan S. Fridman, Timothy C. Burn, Andrew P. Combs, Robert C. Newton, Peggy A. Scherle
Journal: Blood
Blood (2010) 115 (17): 3520–3530.
https://doi.org/10.1182/blood-2009-09-246124
Published: 2010
Journal Articles

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Solly George, Rn, Carol Bivins, Rn, Jorge Cortes-Franco, MD, William M Garrett, MBA, Robert C Newton, PhD, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 631.
https://doi.org/10.1182/blood.V114.22.631.631
Published: 2009
Journal Articles

The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2

Ayalew Tefferi, MD, Hagop M Kantarjian, Animesh D. Pardanani, MBBS, PhD, Ruben A. Mesa, MD, FACP, Robert C Newton, PhD, Peggy A Scherle, PhD, Timothy Burn, PhD, Srdan Verstovsek
Journal: Blood
Blood (2008) 112 (11): 2804.
https://doi.org/10.1182/blood.V112.11.2804.2804
Published: 2008